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In order to test the hypothesis that Wegener’s
granulomatosis (WG) is associated with an ongoing immune
effector response, even in remission, we examined the
distribution of peripheral naive and memory T-lymphocytes
in this disease, and analyzed the function-related phenotypes
of the memory T-cell population. Peripheral blood
mononuclear cells (PBMCs) were freshly isolated from
WG-patients in remission (R-WG, n¼ 40), active WG-patients
(A-WG, n¼ 17), and age-matched healthy controls (HCs,
n¼ 21). Expression of CD4, CD8, CD45RO, CCR7, interleukin
(IL)-18Ra, ST2L, and FoxP3 were determined by four-color
flow cytometric analysis. CD45RO and CCR7 were used for
distinction between naive and memory T cells, IL-18Ra, ST2L,
and FoxP3 for the assessment of Type1, Type2, and
regulatory T-cells, respectively. In R-WG, the CD4þCD45ROþ
CCR7 effector memory T-cell subpopulation (TEM) was
relatively increased, whereas the CD4þCD45ROCCR7þ
naive T-cell population (TNaive) was decreased as compared to
HC. The distribution of naive and memory CD8þT cells did
not differ between R-WG, A-WG, and HC, nor did
CD4þCD45ROþCCR7þ central memory T cells (TCM). In
contrast to HC, the percentage of CD4þTNaive cells in R-WG
correlated negatively with age, whereas CD4þTEM cells
showed a positive correlation. In R-WG, a skewing towards
Type2 T cells was observed in CD4þTEM cells. No differences
were detected in FoxP3þCD4þTEM cells between R-WG
and A-WG, whereas the FoxP3CD4þTEM cells were increased
in R-WG and decreased in A-WG as compared to HC.
Collectively, peripheral blood homeostasis of CD4þT cells
is disturbed in R-WG with the persistent expansion of
non-regulatory CD4þTEM cells. These cells might be involved
in relapse and may constitute a target for therapy.
Kidney International (2006) 70, 938–947. doi:10.1038/sj.ki.5001670;
published online 12 July 2006
KEYWORDS: Wegener’s granulomatosis; T cells; central memory T cells;
effector memory T cells
Wegener’s granulomatosis (WG) is an autoimmune disease of
unknown etiology characterized by necrotizing granuloma-
tous lesions in the respiratory tract, systemic vasculitis
affecting small- to medium-sized vessels, and pauci-immune
glomerulonephritis.1 Although remission can be obtained in
the vast majority of patients by immunosuppressive treat-
ment, relapses occur in most patients.2
Over the past decade, several studies have implicated T
cells in the pathogenesis of WG. The presence of T-cell
infiltrates in granulomatous lesions, vasculitic areas, and
affected kidneys,3–7 as well as the possibility of obtaining
remission in refractory Wegener’s patients by treatment with
humanized monoclonal antibodies specific to lymphocyte
CD52 and CD4 antigens and rabbit anti-thymocyte globu-
lin,8,9 support the view that T cells play a major role in the
pathogenesis of WG. Furthermore, increased levels of T-cell
activation markers such as soluble interleukin-2 receptor
(sIL-2R), soluble CD4 and soluble CD30, and upregulation of
CD25 and human lymphocyte antigen-DR (HLA-DR) on
circulating T cells in active WG (A-WG), and even during
complete remission, indicate continuous T-cell activity.10–14
These activated lymphocytes expressed CD45RO, implicating
memory T cells in WG.15 Indeed, lymphocytes accumulating
in lung lesions of A-WG-patients demonstrate a T-helper-2
(Th2) environment16 and appear to consist mainly of
CD4þCD45ROþ T cells and, although less numerous,
CD8þCD45ROþ T cells.17
Recent reports indicate the existence of two major
subpopulations of human memory T cells, which are defined
by the expression of the lymph node homing chemokine
receptor CCR7.18,19 Central memory T cells (TCM) express
CCR7 and efficiently home to lymph nodes, whereas effector
memory T cells (TEM), which lack CCR7 expression, fail to
migrate to lymphoid organs, but have acquired the capacity
to migrate to inflamed peripheral tissues and display
immediate effector functions.
In view of the relapsing course of WG, in which relapses
are possibly elicited by local inflammatory stimuli,20 we
hypothesized that an expanded population of effector
memory T cells is persistently present also in patients in
remission. Upregulation of CCR3- and CCR5 chemokine
receptors mediating the entrance of T cells into the site of
inflammation has been observed in CD4 and CD8 memory
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T cells in peripheral blood of WG-patients.21 This suggests
that these cells belong to the population of effector memory
T cells. Once disease activity is present, these cells can be
recruited from the peripheral blood to the site of inflamma-
tion, resulting in perturbation in T-cell homeostasis in the
peripheral blood.
In order to test this hypothesis, we studied the distribution
of circulating naive T cells and central and effector memory
T-cell subpopulations by analyzing the expression of
CD45RO and CCR7 markers on CD4 and CD8 T cells in
patients with WG in remission in comparison with active
patients and healthy controls (HCs). To assess skewing of the
respective T-cell subpopulations into Type1 and Type2
T cells, we determined the expression of Type1-associated
IL-18Ra and Type2-associated ST2L surface markers.22 The
results show that WG-patients in remission demonstrate
a persistent expansion of Th2 effector memory T cells with
a concomitant decrease of naive CD4þT cells in their
peripheral blood.
RESULTS
The percentage of circulating T-cell subsets
A decrease in the percentage of CD4þT cells and an increase
in the percentage of CD8þT cells were detected in R-WG-
patients and patients with A-WG, as compared to HC, but
the difference was significant for R-WG-patients only. The
CD4/CD8 T cell ratio was significantly lower in R-WG-
patients than in HC. This was not the case for patients with
A-WG. No difference was observed in the percentage of
CD4þT cells, CD8þT cells, or CD4/CD8 ratio between both
patients groups (Table 2).
Percentages of circulating CD4þ memory T cells are
increased in WG-patients in remission
We determined the percentages of total memory cells
(CD45ROþ ) of CD4þ and CD8þT cells in HC, and in
A-WG-patients and R-WG-patients (Figure 1a). The percentage
of CD4þ memory T cells was significantly increased in
R-WG-patients but not in patients with A-WG, as compared
to the HC group. The percentages of CD8þ memory T cells
from either A-WG-patients or R-WG-patients did not differ
from that of HC. No differences were seen in the percentages
of memory T cells neither between patients with localized
and generalized active disease nor between patients with
localized and those with generalized disease in remission
(Figure 1a).
Increased effector memory and decreased naive CD4þT cells
in WG-patients in remission
To address the question whether the increase in memory T
cells is accompanied by a reciprocal decrease in naive T cells
and to define the phenotype of the expanded memory T-cell
population, we analyzed the percentages of naive T
cells (TNaive) and the two memory subsets (TCM and TEM)
of CD4þ and CD8þT cells as based on the expression of
CCR7 and CD45RO. Naive (CD45RO) and central memory
(CD45ROþ ) T cells are positive for CCR7, whereas effector
memory (CD45ROþ ) T cells lack CCR7 expression.
Within the CD4þT-cell population, R-WG-patients had
a significantly lower percentage of CD45ROCCR7þTnaive
cells, and a significant increase in the percentage of
CD45ROþCCR7TEM cells as compared to the control
group (Figure 1b and c). In contrast, the percentages of
CD45ROþCCR7þTCM and CD45RO
CCR7 terminally
differentiated effector memory T cells (TtEM) in R-WG-
patients did not differ from that in HC. No significant
differences were found in the CD4þT-cell subpopulations
between A-WG-patients and HC (Figure 1c). The percentages
of CD8þT-cell subpopulations from either A-WG-patients or
R-WG-patients did not differ from that in HC.
Next, we assessed whether the absolute counts of T-cell
subpopulations, in addition to their proportions, reflect the
same disturbance in CD4þT-cell homeostasis. As lympho-
penia is not infrequent in WG-patients, we compared ratios
of absolute counts of lymphocyte subpopulations between
Table 1 | Clinical and laboratory characteristics
of WG-patients
Remission
(n=40)
Active
(n=17)
Sex (M/F) 24/16 10/7
Age (years, median (range)) 57 (17–87) 55 (19–85)
BVAS (mean (range)) 0 11 (6–25)
Loc./gen. 8/32 9/8
ANCA (+/) 30/10 15/2
Treatment (yes/no) 11/29 3/14
CRP (mg/l, mean (range)) 7.6 (2.7–35) 76 (2.7–163)
Disease duration (months, median (range)) 78 (11–192) 0 (0–203)
Number of relapses (median (range)) 1 (0–4) 0 (0–3)
ANCA, anti-neutrophil cytoplasmic antibody; BVAS, Birmingham Vasculitis Activity
Score; CRP, C-reactive protein; F, female; gen., generalized; loc., localized; M, male;
WG, Wegener’s granulomatosis.
Table 2 | Percentage of CD4 and CD8 T cells in peripheral blood of WG-patients in remission or with active disease compared
to HCs
HCs (n=21) Remission (n=40) P-value Active (n=17) P
CD4+ T cells 50.3671.58 41.5671.85 0.002 48.0573.28 NS
CD8+ T cells 21.2871.21 28.8671.90 0.004 27.1672.92 NS
CD4/CD8 2.5270.15 1.8370.22 0.0002 2.3670.39 NS
HC, healthy controls; NS, nonsignificant; P, level of significance.
Values expressed as mean percentage7s.d. P-values for each patient group were calculated relative to HCs.
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R-WG- and A-WG-patients and HC. When cytometry data
were expressed as absolute number, R-WG-patients exhibited
a significant increase in total memory/TNaive, TEM/TCM, and
TEM/TNaive ratios of CD4
þT cells compared to A-WG-
patients and HC (Figure 1d). In contrast, no differences were
observed in the same ratios within CD8þT cells between
either patients with A-WG and R-WG, or between patient
groups and healthy individuals.
Furthermore, no differences were found in T-cell sub-
populations between localized and generalized disease
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Figure 1 | CD4 and CD8 naive and memory T-cell subpopulations in peripheral blood of WG-patients in remission (R-WG, n¼ 40), active
WG-patients (A-WG, n¼ 17), and HCs (n¼ 21). (a) The percentages of total memory cells (CD45ROþ ) within the CD4þ and CD8þ T-cell
population in peripheral blood of HC, R-WG, and A-WG patients. (b) Representative example of multicolor flow cytometric analysis of TNaive
(CCR7þCD45RO), TCM (CCR7
þCD45ROþ ), TEM (CCR7
CD45ROþ ) and TtEM (CCR7
CD45RO) after gating on CD4 or CD8 T cells from a
representative R-WG patient and a sex- and age-matched HC. The fraction of CD4þTEM is increased and the fraction of CD4
þTNaive is decreased
in this R-WG patient as compared to HC, whereas no differences are seen within CD8 T-cell subpopulations. (c) Percentages of TNaive, TCM, TEM,
and TtEM subpopulations within the CD4
þ T cells (left) and CD8þ T cells (right). (d) Ratios of the absolute counts, both for CD4þ and CD8þ
T-cell subpopulations, of total memory/TNaive, TEM/TCM, and TEM/TNaive. The open symbols within the patients groups represent localized
disease, and the solid symbols represent generalized WG. Bars represent mean percentage. The P-values were calculated using the
non-parametric Mann–Whitney U-test.
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(Figure 1) or between anti-neutrophil cytoplasmic antibody
(ANCA)-positive patients or ANCA-negative patients at the
moment of sampling (data not shown).
Longitudinal studies of the expanded CD4þTEM cells
To assess intra-individual variation in CD4þTEM cells over
time, the relative percentages of TEM and the ratios of the
absolute numbers of TEM/TNaive were reanalyzed after a
period of 1572 months in five patients who remained in
remission and in five age-matched HCs (Figure 2). Neither
R-WG-patients nor HCs showed significant changes in
CD4þTEM over time. In addition, we analyzed CD4
þTEM
in paired samples from WG-patients during active disease
and during remission. As shown in Figure 2, the percentages
of TEM and the ratios of the absolute counts of TEM/TNaive in
six patients were significantly higher during remission than in
active disease.
Increase in CD4þTEM cells during remission is not owing to
increase in regulatory T cells.
It has been found that a subset of regulatory T cells (TRegs)
display an TEM phenotype.
23 This observation attempted us
to dissect whether the increased CD4þTEM cells in R-WG-
patients are TRegs. To this end, we examined the expression of
FoxP3, the most accurate marker of TRegs,
24,25 in CD4þTEM
cells from WG-patients and age-matched HCs (Figure 3a).
Although the percentages of FoxP3þCD4þTEM were slightly
increased in R-WG-patients compared to HC, percentages of
FoxP3CD4þTEM were even more increased in R-WG-
patients compared to HCs. As a result, the ratios of
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Figure 2 | Longitudinal analysis of CD4þTEM in WG-patients and
HCs. Percentages (a) of CD4þTEM and ratios of absolute counts (b) of
CD4þTEM/TNaive were analyzed at two time points, 1572 months
apart, in HCs (n¼ 5) and in R-WG-patients during stable remission
(n¼ 5) as well as in patients during active disease and remission
(n¼ 6). Horizontal lines represent the median values. The P-values
were calculated using the Wilcoxon matched-pairs test.
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Figure 3 | Circulating FoxP3þTEM and FoxP3
TEM among CD4
þ
T-cells in WG-patients and HCs. Percentages of FoxP3-positive and
FoxP3-negative CD4þTEM cells (a), and the ratios of FoxP3
CD4þTEM/
FoxP3þCD4þTEM (b) in WG-patients in remission (R-WG, n¼ 5),
patients with active WG (A-WG, n¼ 5), and age-matched HCs (n¼ 5).
FoxP3 expression was determined using an intracellular staining
procedure on PBMCs and data were analyzed on FACS-Calibur.
Horizontal lines represent median values, and P-values were
calculated using the non-parametric Mann–Whitney U-test.
Kidney International (2006) 70, 938–947 941
WH Abdulahad et al.: Effector T cells in Wegener’s granulomatosis o r i g i n a l a r t i c l e
FoxP3CD4þTEM/FoxP3
þCD4þTEM did not differ between
R-WG-patients and HCs, indicating that there is not a
selective increase of FoxP3þ cells within the CD4þTEM
subpopulation. In A-WG-patients, percentages of FoxP3þ
CD4þTEM were not lower than in R-WG. However, percent-
ages of FoxP3CD4þTEM were higher during remission,
although the ratios of FoxP3CD4þTEM/FoxP3
þCD4þTEM
did not differ between A-WG and R-WG (Figure 3a and b).
These data indicate that the increase in CD4þTEM during
remission is not owing to an enrichment of TRegs.
Skewing in CD4þTCM toward Th1 and modulation in
CD4þTEM toward Th2 in peripheral blood of WG-patients
To elucidate the functional role of CD4þT cells in WG-
patients, we determined the percentages of Th1 and Th2 cells
by analyzing the expression of Th1-associated IL-18Ra and
Th2-associated ST2L surface markers.22 We have analyzed the
accuracy of these two markers to distinguish between Th1
and Th2 cells by studying the cytokine profile of CD4þ IL-
18Raþ and CD4þST2Lþ sorted cells. IL-18Raþ cells were
predominantly interferon g (IFNg)-producing cells and were
negative for IL-4, whereas ST2Lþ cells were IL-4-producing
cells and were negative for IFNg (data not shown) analogous
to data of Chan et al.22
As compared to the control group, the percentages of
IL-18RaþCD4þT cells (Th1) were significantly elevated in
A-WG-patients and R-WG-patients, whereas no differences
were seen in the percentages of ST2LþCD4þT cells (Th2)
(Figure 4a). Next, we studied Th1- and Th2- phenotypic
markers of effector- and central memory CD4þT cells
(Figure 4b). In line with previous finding,26 the majority of
CD4þ memory T cells were neither Th1 nor Th2 cells. A
significant increase was observed in the percentage of Th2-
effector memory cells (Th2EM) in R-WG-patients but not in
A-WG-patients when compared to HC, whereas percentages
of Th1-effector memory cells (Th1EM) did not differ.
Percentages of Th1-central memory cells (Th1CM) were
increased in A-WG-patients and R-WG-patients, whereas
no difference was seen in the percentage of Th2-central
memory cells (Th2CM) between patients and HC. No
differences were found between patients with localized and
generalized WG (Figure 4a and b) or between ANCA-positive
and ANCA-negative patients at the time of sampling with
respect to Th1- and Th2- profiles, both in CD4þTCM and
CD4þTEM cell population (data not shown).
Therapy and the imbalance in CD4þT-cell subpopulations
and Th1/Th2 skewing in R-WG-patients
To address the question whether current treatment influences
the imbalance in CD4þT-cell subpopulations, the R-WG-
patients group was separated into untreated (n¼ 29)
and treated patients (n¼ 11), and the percentages of the
CD4þT-cell subpopulations and Th1/Th2 subsets were
compared. No significant differences were found between
the treated and untreated group (Table 3). It seems, therefore,
that current treatment is not responsible for imbalances and
Th1/Th2 skewing within the CD4þT-cell subpopulations.
Also, we analyzed whether distribution of T-cell subsets
was influenced by the absolute numbers of lymphocytes. No
relation was found between any of the phenotypically defined
lymphocyte subsets and absolute lymphocyte counts (data
not shown).
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Figure 4 | Cell surface expression of IL-18Ra and ST2L markers. Expression of IL-18Ra and ST2L on (a) total CD4þ T cells and (b) CD4
central (TCM) and effector (TEM) memory T cells in peripheral blood of WG-patients in remission (R-WG), active WG-patients (A-WG) and HCs.
Horizontal lines represent mean percentage. The open symbols within the patients group represent localized disease, and the solid
symbols represent generalized WG. The P-values were calculated using the non-parametric Mann–Whitney U-test.
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CD4þT-cell subpopulations in R-WG-patients correlate with
age but not with disease duration or relapses
It has been reported that memory T cells increase with age.27
However, changes in the distribution between central and
effector memory and naive T cells in relation to age have not
been reported. We found a significant negative correlation
between the percentages of naive CD4þT cells and age in
WG-patients in remission (P¼ 0.0003, r2¼ 0.3) (Figure 5a).
Conversely, a positive significant correlation was found
between age and the percentage of CD4þTEM cells in the
same patient group (P¼ 0.002, r2¼ 0.22). No such correla-
tions were detected in HC (Figure 5b). The percentage of
central memory CD4þT cells did not correlate with age in
either patients or HC. We did not find a significant
correlation between CD4þ T-cell subpopulations and disease
duration or number of relapses in R-WG-patients (data not
shown).
DISCUSSION
The present study demonstrates a skewed phenotype of
circulating CD4þT-cell subpopulations in R-WG-patients,
resulting in relative increase in CD4þTEM cells with a
concomitant decrease in CD4þTNaive cells. In addition, the
expanded CD4þTEM cells were mostly FoxP3-negative and
skewed toward a Th2 phenotype. The persistent expansion of
CD4þTEM at the cost of a reciprocal reduction in naive
CD4þT cells in the peripheral blood of R-WG-patients may
result from a persistent antigenic stimulus and may point to
the presence of an ongoing immunological stimulus as the
basis for the frequent relapsing course of WG. To our
knowledge, this is the first report demonstrating a shift from
naive towards CD4þTEM cells in WG-patients.
Activation and differentiation of CD4þTNaive cells to-
wards TEM cells is dependent on the strength of the antigenic
stimulation. CD4þTNaive cells that receive a weak stimulus
Table 3 | Comparison of CD4+ T-cell subpopulations, and Th1/Th2 subsets in untreated and treated WG-patients in remission
Untreated R-WG (n=29) Treated R-WG (n=11) P-value
% TNaive (CD4
+CD45ROCCR7+) 20.2772.45 21.8574.11 NS
% TCM (CD4
+CD45RO+CCR7+) 28.0571.47 29.8772.12 NS
% TEM (CD4
+CD45RO+CCR7) 46.0072.76 41.2873.22 NS
% TtEM (CD4
+CD45ROCCR7) 5.6870.93 6.9972.07 NS
% Th1EM (CD4
+IL-18Ra+TEM) 13.2871.48 9.9471.15 NS
% Th1CM (CD4
+IL-18Ra+TCM) 4.9970.4 6.0671.07 NS
% Th2EM (CD4
+ST2L+TEM) 1.1770.08 1.1770.15 NS
% Th2CM (CD4
+ST2L+TCM) 1.0470.08 0.9670.1 NS
NS, nonsignificant; P, level of significance; R-WG, WG-patients in remission; TCM, CD4
+CD45RO+CCR7+ central memory T cells; TEM, CD4
+CD45RO+CCR7 effector memory
T cells; TtEM, CD4
+CD45ROCCR7 terminally differentiated effector memory T cells; Tnaive, CD4
+CD45ROCCR7+ naive T cells; Th1CM, Th1-central memory cells; Th1EM,
Th1-effector memory cells.
Nine of the patients were treated with azathioprine, one patient with cyclophosphamide, and one patient received cyclophosphamide with a low dose of prednisolone.
Values expressed as mean percentage7s.d.
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Figure 5 | Correlation between age (in years) and the percentage of CD4þTNaive, TCM, and TEM cell subpopulations. (a) CD4
þTEM cells
increase significantly, whereas CD4þTNaive cells show a significant decrease with age in WG-patients in remission. (b) No such correlations
are seen in healthy individuals. The r2 and P-values were calculated using linear regression.
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proliferate to a TCM pool, whereas priming by a strong
stimulus results in differentiation towards TEM cells.
28,29 In
addition, persistence of an immune trigger is required to
maintain CD4þTEM but not CD4
þTCM cells.
30 This may
indicate that the expanded CD4þTEM cell population in WG
is generated via a strong and persistent antigenic trigger of
naive T cells. Likewise, these data are in line with the
observation that in many patients with WG markers of
ongoing T-cell activation are present during disease remis-
sion.14 As myelin-specific T cells from multiple sclerosis
patients exhibit a TEM-phenotype
31 and the latter cells induce
experimental autoimmune encephalomyelitis via passive
transfer from diseased rats into naive rats,32 it is tempting
to speculate that also in WG, the size of the persistent
CD4þTEM pool may be related to the extent of the disease or
the propensity to relapse. This has also been suggested for
persistent memory T cells in polymyositis and in an animal
model for psoriasis.33,34
Based on our results (Table 3), it is highly unlikely that the
observed skewing towards the CD4þTEM is owing to
previous exposure to immunosuppressive medication, as
the skewed phenotype did not correlate with disease duration
or number of relapses. These data also suggest that the
antigenic stimuli responsible for the expanded CD4þTEM
pool are present irrespective of disease activity. As memory
T cells increase with age,27 we also examined the impact of
age on the skewed phenotype of circulating CD4þT cells.
Interestingly, CD4þTNaive cells decreased significantly,
whereas CD4þTEM showed a significant increase with age
in R-WG-patients, in contrast to HC. Although our group of
HC had the same age distribution as our patient group, the
control group was rather small, which may have obscured a
relation between age and memory T cells in the latter group.
On the other hand, HCs may lack a chronic (auto)-
immunogenic stimulus responsible for the production of
CD4þTEM present in WG-patients.
Very recently, it was shown that TRegs may display a TEM-
like phenotype and that these TRegs are the most potent
suppressors of inflammatory processes in disease models.35 If
this were the case in WG, one may argue that the increased
CD4þTEM-pool in WG-patients might be responsible for
maintaining remission. To investigate this possibility, FoxP3
expression was assessed in CD4þTEM cells. However, no
significant difference was observed in the percentages of
FoxP3þCD4þTEM between R-WG-patients and patients with
A-WG. Thus, the increase in CD4þTEM during remission
cannot be explained by increase in TRegs.
Both our cross-sectional and follow-up data demonstrate
that levels of circulating CD4þTEM in A-WG-patients are
significantly lower than in R-WG-patients, and the majority
of these CD4þTEM were negative for FoxP3. A decrease in
FoxP3CD4þTEM cells may have occurred in A-WG-patients
owing to migration of those cells into sites of inflammation
during active disease. Factors triggering initial disease and
relapse are presently unknown but may be local events
resulting in local upregulation of adhesion molecules and
chemokine receptors for CD4þTEM cells mediating their
migration. Indeed, in active pulmonary lesions in patients
with WG, CD4þT cells with a memory phenotype were
observed.17 In addition, CD4þCD28T cells with a memory
phenotype have been found enriched in granulomatous
lesions of the respiratory tract and bronchoalveolar lavage
fluid in A-WG.36 Studies in mice and humans have
confirmed an important role for CD4þT cells in initiating
and maintaining granuloma formation.37,38 Furthermore,
enrichment of CD4þTEM cells was demonstrated in synovial
fluid of patients with juvenile idiopathic arthritis and in renal
biopsy specimens of patients with post-infectious glomer-
ulonephritis, and also in skin lesions of patients with
psoriasis.39–41 So it is conceivable that the CD4þTEM cells
in active disease have migrated towards the tissues.
In an attempt to further elucidate the functional
phenotype of circulating CD4þT-cells in WG-patients, we
determined the expression of Type1-associated IL-18Ra and
Type2-associated ST2L surface markers on circulating CD4þ
memory T cells. A previous report on the expression of
chemokine receptors associated with Th1 and Th2 cells in
healthy individuals demonstrated that 77% of circulating
CD4þ memory T cells are unable to produce Th1 or Th2
cytokines.26 Consistent with this, we found that only a
minority of circulating CD4þ memory T cells expressed
IL-18Ra or ST2L. In accordance with previous reports,42,43
we found an increase in circulating Th1 cells (IL-18Raþ
CD4þT cells) in WG-patients. In contrast with data of
others,44,45 we observed a skewing towards Th2 in the TEM
cell population in R-WG-patients only, whereas the TCM cells
skewed towards Th1 cells in both A-WG-patients and R-WG-
patients. Disappearance of Th2EM skewing in A-WG-patients
may result from migration of Th2EM cells into sites of
inflammation. Although percentages of Th2EM cells in
ANCA-positive patients were slightly, but not significantly,
higher than in ANCA-negative patients, CD4þTEM cells
might be implicated in humoral immunity and ANCA
production. On the other hand, it has been reported that
proteinase-3 (PR3) and myeloperoxidase (MPO), the main
target antigens of ANCA, induce a Th2 skewed cytokine
pattern in R-WG-patients.46 In addition, Balding et al.16 have
demonstrated a Th2 response in nasal mucosa in A-WG.
Furthermore, stimulation of peripheral blood mononuclear
cells (PBMCs) from WG-patients with Staphylococcus aureus
induced a Th2 cytokine profile,47 and chronic nasal carriage
of S. aureus has been reported to be a strong risk factor for
relapse in WG and to be associated with ANCA positivity.20
These latter findings support the hypothesis that the
expansion of Th2EM that we found in R-WG-patients may
result from stimulation with super-antigens, as can be
derived from S. aureus, or with the auto-antigens PR3 or
MPO.
In conclusion, the data presented demonstrate an increase
in the percentage of non-regulatory CD4þTEM cells with a
reciprocal decrease in CD4þTNaive cells in conjunction
with a skewing towards Th2EM in the peripheral blood of
944 Kidney International (2006) 70, 938–947
o r i g i n a l a r t i c l e WH Abdulahad et al.: Effector T cells in Wegener’s granulomatosis
R-WG-patients. This suggests a persistent immune response,
also during inactive disease, towards an as yet unknown
antigenic stimulus. The FoxP3CD4þTEM cells probably
migrate to the site of inflammation once disease activity
occurs and the persistence of the CD4þTEM pool may
underlie the remitting course of this disease.
MATERIALS AND METHODS
Study population
Fifty-seven consecutive patients with WG (Table 1) and 21 age-
matched HC (nine men, 12 women, mean age 51 years, range 20–83
years) were enrolled in this study. All patients and healthy
individuals provided informed consent and the local medical ethics
committee approved the study. All patients met the criteria of the
American College of Rheumatology48 and the Chapel Hill
Consensus Conference49 definition for WG. Disease activity was
assessed for all patients at the time of sampling using the
Birmingham Vasculitis Activity Score (BVAS).50 Remission was
defined as the complete absence of disease symptoms. Disease
extension was defined as localized when WG was restricted to the
upper and lower respiratory tract and as generalized when systemic
disease with vasculitis including renal disease was present. A relapse
of the disease was considered on the basis of clinical and laboratory
signs of inflammation and signs of a new or worsening clinical
manifestation of WG. According to these criteria, blood samples
were taken during a clinically active phase of disease in 17 patients
(nine localized and eight generalized) and during remission in 40
patients (eight localized and 32 generalized). None of the patients
with A-WG or R-WG experienced an infection at the time of
sampling.
Three of 17 patients with active-WG (A-WG) were still being
treated with maintenance immunosuppressive therapy when they
had relapsed and blood was sampled. One patient received
mycophenolate mofetil with low-dose prednisolone and two
patients were treated with azathioprine. Within the group of WG-
patients in remission (R-WG), 29 patients did not receive any
therapy at the time of sampling, whereas nine patients were treated
with azathioprine, one patient with cyclophosphamide, and one
patient received cyclophosphamide with low-dose prednisolone. Ten
of the 17 active patients were studied at the first manifestation of
their disease, and the remaining active patients were analyzed at the
time of relapse. The mean level of C-reactive protein (CRP) in the
group of A-WG-patients was significantly higher than in the group
of R-WG-patients (Po0.0001).
Laboratory parameters
Plasma levels of CRP were measured by nephelometry (Behring
Marburg, Germany).51 ANCA titers were measured by indirect
immunofluorescence on ethanol-fixed human granulocytes, accord-
ing to the standard procedure as described previously.52 ANCA titers
lower than 1:20 were considered negative.
Isolation of PBMCs
Peripheral blood was obtained by venipuncture in heparinized
tubes, and PBMCs were immediately isolated by density-gradient
centrifugation on Lymphoprep (Axis-Shield PoC AS, Oslo, Norway).
Cells were washed two times in phosphate-buffered saline (pH 7.2),
and resuspended at 5 106 cells/ml in RPMI 1640 (Cambrex Bio
Science, Verviers, Belgium) supplemented with 5% human pool
serum and 50 mg/ml gentamycin (Gibco, Scotland, UK). Cells were
stained immediately and analyzed by fluorescence-activated cell
sorter (FACS).
Antibodies
The following antibodies were used in flow cytometry: peridin-chloro-
phyll (PerCP)-conjugated anti-CD4, PerCP-conjugated anti-CD8,
phycoerythrin (PE)-conjugated anti-CCR7, fluorescein isothio-
cyanate (FITC)-conjugated anti-CD45RO, and allophycocyanin (APC)-
conjugated anti-CD45RO. All were purchased from Becton &
Dickinson (Amsterdam, The Netherlands). FITC-conjugated IL-18Ra
and APC-conjugated anti-FoxP3 were obtained from eBioscience
(San Diego, CA, USA) and FITC-conjugated ST2L was purchased
from MD Biosciences (Division of Morwell Diagnostic GmbH;
MD Biosciences, Zurich, Switzerland). MultiTEST four-color
antibodies (FITC-anti-CD3, PE-anti-CD8, PerCP-anti-CD45, and
APC-anti-CD4) were purchased from Becton & Dickinson. Isotype-
matched control antibodies of irrelevant specificity were obtained
from Becton & Dickinson and eBioscience.
Flow cytometry analysis
PBMCs (0.5 106 cells/100ml) from WG-patients and HCs were
stained immediately after blood drawing with appropriate concen-
trations of fluorochrome-conjugated monoclonal antibodies for cell
surface antigens. Four-color flow cytometric analyses were per-
formed using the following monoclonal antibodies: FITC- or
allophycocyanin-anti-CD45RO, PE-anti-CCR7, PerCP-anti-CD4 or
PerCP-anti-CD8, and FITC-anti-IL-18Ra or FITC-anti-ST2L. After
the addition of monoclonal antibodies and incubation for 15 min at
room temperature, 2 ml of 1 FACS lysing solution (Becton &
Dickinson) was added, and samples were washed in phosphate-
buffered saline containing 1% bovine serum albumin and
immediately analyzed by flow cytometry. To determine the
frequency of TRegs, surface staining was followed by intracellular
staining for FoxP3 protein performed by using fixation and
permeabilization buffers provided by the FoxP3-kit (eBioscience)
according to the manufacturer’s instruction. Four-color staining was
analyzed on FACS-Calibur (Becton & Dickinson) and data were
collected for 3 104 lymphocytes gated by forward and side scatter.
Data were plotted using the Win-List software package (Verity
Software House Inc., ME, USA). Positively and negatively stained
populations were calculated by quadrant dot-plot analysis, deter-
mined by the appropriate isotype controls.
Quantification of CD4þ and CD8þ T cells
CD4þ and CD8þT cells were quantified by four-color FACS-
Calibur flow cytometer using TruCOUNT tubes (Becton &
Dickinson), according to the manufacturer’s instructions. The
absolute number of CD4þ and CD8þT cells was determined by
comparing cellular events to beads events using CELL-Quest
software (Becton & Dickinson).
Statistical analysis
Data are presented as mean7s.d., unless stated otherwise. The non-
parametric Mann–Whitney U-test was used to compare data from
WG-patients with that of HCs. The Wilcoxon matched-pairs test
was used for intra-individual comparison of values at two time
points. Linear regression analysis was performed to assess associa-
tions between the phenotypically defined T-cell subsets and different
parameters. Two-tailed P-values less than 0.05 were regarded as
statistically significant.
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